DCPrime is a clinical stage company which develops novel cancer immunotherapies based on its DCOne®platform technology. This platform combines antigen carrier properties with the immune-stimulatory properties of dendritic cells, and DCOne®‐based vaccines have the simple logistics of off‐the‐shelf products. Based on the promising results of a Phase I/IIa study in Acute Myeloid Leukemia (AML) with its lead product DCP-001, DCPrime is now preparing an international multi-centre Phase II study in post-remission AML patients with DCP-001. DCPrime is also pursuing development of DCP-001 for another hematological cancer, Multiple Myeloma (MM). For development of DCOne®-based vaccines in solid cancers, DCPrime has established antigen-loading procedures which it is now testing pre-clinically.